Australia markets closed

Catalyst Biosciences, Inc. (CBIO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.7900+0.0100 (+0.56%)
At close: 04:00PM EDT
1.7600 -0.03 (-1.68%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.7800
Bid1.7600 x 3200
Ask1.8000 x 1100
Day's range1.7500 - 1.8398
52-week range0.3500 - 5.2000
Avg. volume6,517,048
Market cap56.344M
Beta (5Y monthly)1.90
PE ratio (TTM)N/A
EPS (TTM)-2.5480
Earnings date03 Aug 2022 - 08 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend date20 Aug 2015
1y target est15.50
  • GlobeNewswire

    Catalyst Biosciences Announces Plan to Distribute Cash to Stockholders

    Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders Decision Follows Recent Sale of Certain Assets and Extensive Engagement with Stockholders Board Will Set Initial Distribution Date and Amount Once Potential Liability and Expenses Associated with Stockholder Litigation and Proxy Contest Are Known SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (the “Company” or “we”) today announced its intention to

  • Zacks

    Has Catalyst Biosciences (CBIO) Outpaced Other Medical Stocks This Year?

    Here is how Catalyst Biosciences, Inc. (CBIO) and Humana (HUM) have performed compared to their sector so far this year.

  • GlobeNewswire

    Catalyst Biosciences Sells Complement Portfolio for $60 Million

    SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) under which Vertex has acquired Catalyst’s portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash. Management Comments“We have been exploring strategic alternatives to monetize our assets and maximize value f